The latest price target for Unity Biotechnology (NASDAQ:UBX) was reported by Chardan Capital on April 23, 2025. The analyst firm set a price target for $4.00 expecting UBX to rise to within 12 months (a possible 394.19% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Unity Biotechnology (NASDAQ:UBX) was provided by Chardan Capital, and Unity Biotechnology maintained their buy rating.

The last upgrade for Unity Biotechnology Inc happened on November 16, 2023 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for Unity Biotechnology Inc.

The last downgrade for Unity Biotechnology Inc happened on June 26, 2023 when Wedbush changed their price target from $3 to $2 for Unity Biotechnology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Unity Biotechnology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Unity Biotechnology was filed on April 23, 2025 so you should expect the next rating to be made available sometime around April 23, 2026.

While ratings are subjective and will change, the latest Unity Biotechnology (UBX) rating was a maintained with a price target of $4.00 to $4.00. The current price Unity Biotechnology (UBX) is trading at is $0.81, which is out of the analyst’s predicted range.